Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience (TWST): insider equity award update. President and COO Patrick John Finn acquired 79,785 shares of common stock at $0 on October 28, 2025, recorded as an “A” (acquisition). Following this transaction, he beneficially owns 286,280 shares directly. The shares reflect Performance Stock Units for which target criteria were determined to have been met on October 28, 2025. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration as provided in the award agreement.
Twist Bioscience (TWST): Form 4 insider update. Company officer Dennis Cho reported acquisition of 29,518 shares of common stock on 10/28/2025 at a price of $0, reflecting Performance Stock Units (PSUs) with target criteria determined to be met. Following this transaction, beneficial ownership stands at 128,228 shares, held directly.
The filing notes that 60% of these PSUs remain subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent on continued service or potential acceleration under the award agreement. Role: Senior Vice President, Chief Legal Officer & Corporate Secretary.
Twist Bioscience (TWST) reported an insider equity award. The company’s SVP of Human Resources acquired 35,513 shares of common stock at $0 on October 28, 2025, tied to Performance Stock Units whose target criteria were met.
Following the transaction, the reporting person beneficially owns 150,191 shares. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, contingent on continued service or acceleration as provided in the agreement.
Twist Bioscience (TWST) reported an insider equity award for its CEO and director, Emily M. Leproust. On 10/28/2025, she acquired 168,976 shares of common stock at $0, tied to Performance Stock Units whose target criteria were determined to have been met. The filing notes that 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement.
Following the transaction, Leproust beneficially owns 770,188 shares directly. The filing also lists existing employee stock options, including grants with exercise prices of $8.82, $26.66, $23.33, and $67.85, with various vesting and expiration terms as disclosed.
Twist Bioscience (TWST) reported an equity award to its Chief Accounting Officer, Robert F. Werner. A Form 4 shows an acquisition of 5,633 shares at $0 on October 28, 2025, tied to performance stock units where target criteria were met.
According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement. Following the transaction, beneficial ownership stands at 52,046 shares, held directly.
Twist Bioscience (TWST) reported an insider equity award. CFO Adam Laponis acquired 25,000 shares of common stock at $0 on October 28, 2025, tied to performance stock units whose target criteria were determined to have been met on that date.
After the transaction, he beneficially owned 116,525 shares, held directly. Per the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or potential acceleration under the agreement.
Twist Bioscience (TWST) disclosed a Form 4 for its President and COO, Patrick John Finn. On 10/23/2025, he sold 2,240 shares of common stock at $30.875 per share.
The filing explains the sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting of Restricted Stock Units, and it does not represent discretionary trading. After this transaction, Finn beneficially owned 206,495 shares, held directly.
Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis reported two planned equity sales under Rule 10b5-1 and company tax-withholding procedures. On 10/08/2025 he sold 3,000 shares at $31.15 under a pre-established trading plan adopted on 05/08/2025. On 10/09/2025 he sold 2,517 shares at $32.922 to satisfy tax withholding for vested restricted stock units; the filing notes these "sell to cover" sales are mandatory under the equity incentive plan and not discretionary. Following these transactions he beneficially owned 91,525 shares.
Twist Bioscience Corp reported a notice of proposed sale under Rule 144 for 2,517 common shares held at Fidelity Brokerage Services LLC with an aggregate market value of $82,864.17. The filing shows these shares were acquired on 10/08/2025 through restricted stock vesting and were received as compensation. The sale is scheduled to occur approximately on 10/09/2025 on NASDAQ. The filer also disclosed sales by Adam Laponis during the past three months totaling 12,242 shares for gross proceeds of $399,803.08, with individual sale dates of 07/09/2025, 08/21/2025, 10/06/2025, and 10/08/2025. Total shares outstanding are listed as 60,360,925. The notice includes the standard signer representation that no undisclosed material adverse information is known.
Twist Bioscience Corp (TWST) chief financial officer Adam Laponis sold shares to cover tax withholding tied to vested performance stock units. On 10/06/2025 the filing shows a sale of 5,875 shares at $32.187 per share as a mandatory "sell to cover" for tax obligations. After the sale the reporting person beneficially owned 97,042 shares. The form clarifies these were not discretionary trades but sales required under the company's equity plan to satisfy withholding.